{"cluster": 20, "subcluster": 81, "abstract_summ": "Conclusions We have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum.CONCLUSIONS: we have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum.Inactivation of specimen did not affect assay measurement.Inactivation of specimen does not affect assay measurement.CONCLUSION: The Abbott SARS-CoV-2 IgG test has high specificity.", "title_summ": "Validation and Performance Comparison of Three SARS-CoV-2 Antibody AssaysMulti-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection KitSide by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificityPerformance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in IdahoEVALUATION OF THE ABBOTT SARS-COV-2 IG-G ASSAY.Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assayCorrelation of ELISA based with random access serologic immunoassays for identifying adaptive immune response to SARS-CoV-2Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infectionComparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samplesTest performance evaluation of SARS-CoV-2 serological assaysAssessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patientsDiagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassaysDevelopment and Multicenter Performance Evaluation of The First Fully Automated SARS-CoV-2 IgM and IgG ImmunoassaysEVALUATION OF THE ROCHE ELECSYS ANTI-SARS-COV-2 ASSAY.Evaluation of nine commercial SARS-CoV-2 immunoassaysEvaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreakReliability of serological tests for COVID-19: Comparison of three immunochromatography test kits for SARS-CoV-2 antibodies.Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays.Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.", "title_abstract_phrases": "Conclusions We have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum.CONCLUSIONS: we have developed fully automated immunoassays for detecting SARS-CoV-2 IgM and IgG antibodies in human serum.Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assayObjectives: To assess the performance (sensitivity and specificity) of the Abbott Architect SARS-CoV-2 IgG antibody assay across three clinical settings.None of these methods, however, are useful in early diagnosis of SARSCoV- 2.Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infectionOBJECTIVE: This study aimed to evaluated the diagnostic performance of the Abbott Architect SARS-CoV-2 IgG assay in COVID-19 patients.Redefined thresholds, in addition, improved the overall inter-assay agreement, paving the way to a better harmonization of serologic tests."}